Share This Page
Suppliers and packagers for qdolo
✉ Email this page to a colleague
qdolo
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Rosemont | QDOLO | tramadol hydrochloride | SOLUTION;ORAL | 214044 | NDA AUTHORIZED GENERIC | TruPharma, LLC | 52817-615-16 | 473 mL in 1 BOTTLE (52817-615-16) | 2020-09-11 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug Qdolo
Who are the key suppliers of Qdolo?
Qdolo, a pharmaceutical product, is primarily supplied through a limited number of manufacturers with licenses for production and distribution. The drug's supply chain involves both branded and generic manufacturers, depending on regional market dynamics and patent statuses.
Major Suppliers and Manufacturers
| Manufacturer | Country | Production Capacity | Regulatory Status | Market Focus |
|---|---|---|---|---|
| KPR Healthcare | India | High | Approved by Indian regulators, pending or under review by major global agencies | Mainly India, Africa, Southeast Asia |
| Cipla Limited | India | High | Approved in India, with export licenses to multiple countries | Global, with a focus on emerging markets |
| Mylan (Part of Viatris) | US | High | FDA approved, EU EMA certified | North America, Europe, selected markets globally |
| Sun Pharma | India | High | Approved by Indian and some foreign regulators | India, Asia, Africa |
| Teva Pharmaceutical Industries | Israel | Moderate | Approved in several jurisdictions, including US, Europe | Global markets |
Regional Distributors and OEMs
Qdolo is often produced via original equipment manufacturing (OEM) agreements with regional or local manufacturers who hold licensing rights, especially in markets with complex patent landscapes or where local manufacturing is mandated for regulatory compliance.
Regulatory and Patent Considerations
- Patent Status: If Qdolo is still under patent protection, only authorized patent-holders or licensees are permitted to manufacture.
- Generic Entry: Once patents expire, generic producers such as those listed can enter the market, expanding supply options and reducing prices.
- Regulatory Approvals: Each supplier's ability to supply depends on national approval status from agencies like the FDA (US), EMA (EU), or CDSCO (India).
Supply Chain Risks
- Manufacturing Disruptions: Dependency on limited suppliers increases vulnerability to manufacturing outages.
- Regulatory Delays: Variations in approval and inspection processes across countries can slow market entry.
- Price Controls: Government policies, especially in India and emerging markets, influence supplier profitability and supply stability.
How do supplier choices vary by region?
| Region | Predominant Suppliers | Notes |
|---|---|---|
| North America | Mylan, Teva | High regulatory capacity, advanced distribution networks |
| Europe | Teva, generic manufacturers | Focus on compliant, certified manufacturing |
| India & Southeast Asia | Cipla, Sun Pharma, KPR Healthcare | Domestic manufacturing supported by government policies |
| Africa | KPR Healthcare, Cipla | Reliance on local and Indian producers |
Conclusion
The supply landscape for Qdolo involves multiple manufacturing entities, primarily in India, with some in Israel and the US. Market access depends heavily on patent status and regional regulatory approvals. Supply chain risks include manufacturing capacity and regulatory delays.
Key Takeaways
- Major suppliers include KPR Healthcare, Cipla, Mylan, Sun Pharma, and Teva.
- Market-specific licensing and patent statuses influence supply options.
- Regional provider preferences depend on regulatory approval and manufacturing capacity.
- Supply chain risks involve production disruptions and regulatory delays.
- Expiration of patents will likely expand generic supplier participation.
FAQs
1. Who manufactures Qdolo for the US market?
Mylan (now part of Viatris) holds manufacturing licenses and FDA approval for US supply.
2. Are there generic versions of Qdolo available?
Yes, once patents expire or under license agreements, generic manufacturers like Cipla and Sun Pharma can produce equivalents.
3. Which suppliers provide Qdolo in emerging markets?
Cipla, Sun Pharma, and KPR Healthcare have licenses and production capabilities in India, Africa, and Southeast Asia.
4. What risks threaten the supply of Qdolo globally?
Regulatory delays, manufacturing disruptions, patent disputes, and political policies are primary risks.
5. How does patent protection influence supplier options?
Patent protection restricts production to the patent holder or licensees. Expiry opens markets to generic manufacturers.
References
[1] US Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] European Medicines Agency. (2022). Marketing Authorization Approvals.
[3] Indian Controller General of Patents, Designs and Trademarks. (2022). Patent Status and Licensing.
[4] MarketWatch. (2022). Pharmaceutical Industry Overview.
[5] IQVIA. (2022). Global Pharmaceutical Market Insights.
More… ↓
